Scinai Immunotherapeutics Ltd - ADR
SCNI - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$27.03M
Close$
$1.67
251.3% upside
Current Fair Value
251.3% upsideUndervalued by 251.3% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $27.03 Million |
|---|---|
| Enterprise Value | $27.76 Million |
| Earnings per Share | $-36 |
| Beta | 2.13 |
| Outstanding Shares | 57,002,218 |
Return
| Return on Equity | -26.94% |
|---|---|
| Return on Assets | -18.41% |
| Return on Invested Capital | -63.69% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 18.58 |
| Enterprise Value to EBIT | -2.92 |
| Enterprise Value to Net Income | -9 |
| Total Debt to Enterprise | 0.13 |
| Debt to Equity | 0.31 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 24, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
December 2, 2026
EPS Estimate
$-8.50
Consensus analyst estimateRevenue Estimate
$494,553
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Scinai Immunotherapeutics Ltd
26 employees
CEO: Ron Babecoff
biondvax (nasdaq: bvxv) is an innovative biopharmaceutical company developing a universal flu vaccine, designed to provide multi-season and multi-strain protection against most human influenza virus strains, including both seasonal and p...